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Abstract
Background: The difficulties in using formalin-fixed and paraffin-embedded (FFPE) tumour specimens for molecular
marker studies have hampered progress in translational cancer research. The cDNA-mediated, annealing, selection,
extension, and ligation (DASL) assay is a platform for gene expression profiling from FFPE tissue and hence could
allow analysis of large collections of tissue with associated clinical data from existing archives, therefore facilitating
the development of novel biomarkers.
Method: RNA isolated from matched fresh frozen (FF) and FFPE cancer specimens was profiled using both the
DASL whole-genome (WG) platform, and Illumina BeadArray’s, and results were compared. Samples utilized were
obtained from the breast cancer tumour bank held at the Cambridge University Hospitals NHS Foundation Trust.
Results: The number of reliably detected probes was comparable between the DASL and BeadArray platforms,
indicating that the source of RNA did not result in a significant difference in the detection rates (Mean probes- 17114
in FFPE & 17400 in FF). There was a significant degree of correlation between replicates within the FF and FFPE sample
sets (r2 = 0.96–0.98) as well as between the two platforms (DASL vs. BeadArray r2 = range 0.83–0.89). Hierarchical
clustering using the most informative probes showed that replicate and matched samples were grouped into the
same sub-cluster, regardless of whether RNA was derived from FF or FFPE tissue.
Conclusion: Both FF and FFPE material generated reproducible gene expression profiles, although there was
more noise in profiles from FFPE specimens. We have shown that the DASL WG platform is suitable for profiling
formalin-fixed paraffin-embedded samples, but robust bioinformatics analysis is required.
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Background
Formalin-fixed paraffin-embedded (FFPE) samples are a
valuable source of clinical material, with great potential
for predictive and prognostic biomarker discovery. RNA
extracted from FFPE tissue is degraded, and therefore
analysis is difficult since formalin fixing leads to cross-
links with proteins and mono-methanol modification of
nucleotide bases [1–3]. Improvements in technology has
made analysis of this material feasible, with considerable
potential for translational research using FFPE tissue.
The cDNA-mediated, annealing, selection, extension,
and ligation assay (DASL®, Illumina, San Diego) is a
platform that was developed for high-throughput gene
expression analysis of partially degraded RNA. This
assay initially assessed the expression of up to 1536 probes
(a maximum of 512 genes, with three probes per gene)
using 100–200 ng of degraded RNA [4]. A combination of
random hexamers and oligo-dT priming is used for cDNA
synthesis. The assay is designed to analyse 50 bp RNA
fragments, and the sensitivity of the platform is enhanced
by PCR amplification using common primers and by
having 30 replicate beads per probe. These arrays are
assembled randomly, and the position of each probe
is determined following manufacture, which reduces
spatial effects [5].
The initial DASL report showed that reproducible and
disease-specific gene expression profiles can be generated
using FFPE samples up to 10 years old [6]. They also com-
pared gene expression in fresh frozen (FF) and FFPE speci-
mens using eight matched cancer and normal samples, and
derived a signature that could differentiate between cancer-
ous and normal tissue in breast and colorectal cancers.
One of the limitations of the original DASL assay was
the limited number of transcripts interrogated. Hence,
the introduction of the whole-genome DASL assay
(DASL WG), which profiles 24,000 transcripts, repre-
sents a marked improvement. In the initial report [7],
the number and overlap of probes in FFPE samples
compared to matched FF specimens were 88 % and 95 %,
respectively. Furthermore, there was a 74 % overlap
between differentially expressed genes in FF and FFPE
samples. The assay was able to detect 1.5–2-fold changes
in gene expression in FFPE specimens and produced high
self-correlation between replicates (r2 > 0.98). Chien et al.
showed that the DASL WG assay can be used to generate
a signature typical of low-grade serous ovarian carcinoma
and thereby distinguish it from borderline tumours [8].
This was subsequently used to differentiate serous and
borderline tumours in three independent datasets with
80 % sensitivity. Another study investigated the effective-
ness of DASL WG in predicting subtypes of familial breast
cancer from FFPE samples; however the study did not in-
clude a direct comparison with matched FF material [9].
In another study, comparison of expression profiles
between FFPE and corresponding normal FF tissues found
that only one quarter of genes identified in FF samples
were also detected in FFPE samples [10]. Several studies
using DASL have been published, but the majority have
not used matched FF and FFPE samples, or have used dif-
ferent platforms to analyse FF samples [11, 12].
Here, we report a robust assessment of the DASL WG
platform in gene expression profiling of matched FFPE
and FF RNA samples from breast cancers. For orthog-
onal comparison, the same FF samples were also profiled
with the Illumina BeadArray platform.
Methods
Matched FF and FFPE samples from a cohort of breast
cancer patients treated in 1999 at Cambridge University
Hospitals NHS Foundation Trust were obtained from
the tumour bank. This study has been approved by the
Cambridge University Hospital Research Ethics committee.
RNA extraction
Five to eight 5 μm-thick sections were cut from each
block of FFPE tissue, and the samples were deparaffi-
nised with xylene and digested with proteinase K for
14 h. Other steps, including purification and DNase
treatment, were performed according to the manufac-
turer’s protocol, and total RNA was stored at −80 °C
after extraction (Roche high Pure Kit). The FF RNA was
extracted using the Qiagen mirNEasy kit (Qiagen) ac-
cording to the protocol.
Whole-genome DASL
Total RNA extracted from FFPE and FF samples was
converted to cDNA using oligo-dT18 and random nano-
mer primers. Pairs of query oligonucleotides, including
three unique pairs for each of 24,000 genes, were
annealed to complimentary sequences (~50 bp) flanking
the specific cDNA target site. The biotinylated cDNA
was then bound to streptavidin particles, and mis- and
non-hybridised oligonucleotides were washed away. Each
primer had a gene-specific sequence and a universal
PCR primer site; a prolonged annealing time of 16 h was
used, with a temperature gradient from 70 to 30 °C. PCR
was performed using universal primers and a single
colour (Cy3) assay. The amplified cDNA was then dena-
tured with NaOH, precipitated, and washed with 75 % al-
cohol. The cDNA was then re-suspended and hybridised
to Illumina Human Reference 8 BeadArrays for 16 h at
65 °C. The slides were washed and imaged using the
Illumina BeadArray Reader (Illumina, San Diego, CA).
Illumina expression BeadArrays
Total RNA (200 ng) from the same FF tumours assessed
in the DASL WG assay was used to generate cRNA, using
the Illumina TotalPrep RNA amplification kit (Ambion).
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Reverse transcription with the T7 oligo (dT) primer was
used to generate first strand cDNA, from which a second
strand was produced using DNA polymerase. The RNA
was subsequently degraded with RNase H and cleaned-up.
In vitro transcription and biotin-labelled UTP were used
to generate multiple copies of biotinylated cRNA, which
was purified with a filter cartridge and quantified using a
NanoDrop spectrophotometer.
The labelled cRNA target (1.5 μg) was hybridised to
an array according to the Illumina HumanRef-6 BeadAr-
ray protocol. A maximum of 10 μl of cRNA was mixed
with 20 μl of GEX-HYB hybridisation solution. The pre-
heated 30 μl sample was dispensed into the large sample
port of each array and incubated for 18 h at 58 °C at a
rocker speed of five. The samples were hybridised to
Illumina BeadArrays (Human Ref 6) and were washed
according to the standard protocol and scanned with a
BeadArray Reader (Illumina, San Diego, CA).
Analysis of gene expression data
Data from the Illumina microarray experiments were
analysed using BeadStudio® software (Illumina, San
Diego) and R (version 2.6.0) [13].
During this analysis, image files were loaded using the
BeadArray package. The BASH algorithm was used to re-
move spatial artifacts [14]. The algorithm generates a grid
of neighbours for each bead and identifies three types of
defects: compact, diffuse (regions that contain more out-
liers than expected by chance), and extended. The average
intensities of each probe were computed to summarise
replicates and finally the data was quantile normalised.
Data for both experiments was combined to give a total
of 24526 probes. Comparisons between FF (BeadArray)
and FF (WG DASL) and between FF (WG DASL) and
FFPE (WG DASL) were performed using identical probes
with Student’s t-tests. For carrying out comparisons be-
tween frozen samples used in DASL and BeadArray, a lin-
ear model per probe was fitted to detect those showing
substantial differences. All probes with a p-value smaller
than 0.05 were selected for clustering analysis.
For comparisons between paraffin and frozen samples
in the DASL WG assay, a similar linear model was fitted
and the probes with p-value < 0.05 were selected.
Correlations between these types of samples were
computed using all probes and this selection of good
probes. The final subset of probes that were selected in
the platform and the tissue comparisons were used as
input for the final cluster analysis. The data is deposited
in a public data repository.
Results
Samples and quality control
As part of this study, five matched FFPE and FF samples
were profiled in multiple technical replicates using the
DASL WG assay. The eight FF cancers were also profiled
using Illumina BeadArray for inter-platform comparison,
including five described above (Table 1). The size of the re-
covered RNA ranged between 100 and 200 base pairs in
length. RPLP13 QRT-PCR provided a quality control meas-
ure and only samples with a cycle threshold (Ct) value of
22–26 were deemed suitable for further analysis.
Assay performance
To assess the DASL assay performance, the average
number of genes detected above background were com-
pared in the five matched FF and FFPE samples. The
mean number of probes detected above background in
FFPE samples were 17114 (range 15291–18662) and
17400 (range 11763–19320) in FF samples, and more
probes were detected reliably in four of the FF samples
used (Fig. 1b). The mean number of probes detected in
replicates of each sample was 17598 (range 14872–19146)
for FF and 17053 (16769–17773) for FFPE.
The probes were carefully re-annotated according to
alignment characteristics (perfect match, good, bad or
no match) and the signal was compared against these
features to quantify their effect. While there was a sig-
nificant low signal in the no match probes, the perfect
matched probes had the greatest signal as expected.
When the reliability of probe detection and the size of
the genes were investigated, there was a significant dif-
ference. The genes that were shorter were more lilkely
to be reliable than those which are longer. Further, the
proportion of detected probes in FF and FFPE samples
were compared, prior to normalisation, to assess the
quality of the signal in the DASL assay. This showed
that as expected, there is a greater variation in the signal
intensity in the FFPE samples compared to FF samples.
Table 1 Correlation of gene expression between matched FFPE
and FF samples pre- and post-gene selection using the DASL
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The reproducibility of the WG DASL assay for FFPE
(using hierarchical clustering analysis), showed that all rep-
licate FFPE samples clustered together (except for 99028P-
3, which is a single outlier), suggesting that the assay has a
high degree of reproducibility for FFPE analysis.
FFPE vs. FF sample analysis
In order to assess the robustness of the DASL WG plat-
form for analysing FF and FFPE samples, the correlation
between different sample types was computed. It ranged
between 0.83 and 0.89 for all the probes, and improved
to 0.96–0.98 upon gene selection undertaken as de-
scribed in the methods section (Figs. 1 and 2, Table 1).
Hierarchical clustering using the best performing probes
showed significant homogeneity, with profiles from four
of the samples (99085, 99028, 99066 and 99025) clustering
together irrespectively of the origin (Fig. 3). There were
outliers, but these were usually samples with a lower
number of genes detected reliably.
DASL WG assay and Illumina BeadArray
The correlation between all the probes in the DASL WG
and BeadArray was assessed to compare the two platforms.
The correlation ranged between 0.80 and 0.82, and im-
proved to 0.83–0.89 when only the best performing probes
were used for the analysis (Table 1).
Although the DASL WG assay data (using FFPE and
FF samples) and the BeadArray (using only FF speci-
mens) are two independent platforms, hierarchial clus-
tering using all probes showed that samples grouped
according to the RNA sample source and the array
platform used. In fact, all FFPE samples were closer
together in the hierachial clustering tree compared to
FF specimens assessed with the BeadArray. Interestingly,
the FF samples assessed by Illumina BeadArray and DASL
WG did not cluster next to each other, but rather in two
distinct groups.
When the analysis was repeated using only the best per-
forming probes (as described in Methods) matched FF
and FFPE samples clustered together (Fig. 4). This is one
of the first studies to show robustly this signficant overlap
using DASL and BeadArray. Four out of the five tumours
in which gene expression was assessed using both illumina
BeadArray and DASL WG clustered together.
Gene Ontology analaysis was undertaken to assess the
probes that were discorant in the FF and FFPE samples
Fig. 1 a Samples and the number of technical replicates used for the DASL WG and Illumina BeadArray analysis & (b) The number of probes
detected above background from Fresh (F) and FFPE (P) samples in the DASL WG assay
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to get a better understanding of the biological processes
involved (Supplementary File 1). This showed that as far
as the biological procesess are concerned: primary meta-
bolic process and nucleic acide metabolic process were
the two top in this category. While Poly (A) RNA bind-
ing and hetercyclic RNA binging were the top two mo-
lecular functions enriched in this group.
Discussion
This study shows that reliable expression profiles could
be generated from FFPE core biopsy tissue, and this
supports the future investigation of this platform for
analysis of multiple markers in breast cancer. The
ability to use FFPE material makes large collections of
currently unutilised resources available for molecular
Fig. 2 Scatter plots showing correlations of gene expression between FF vs. FFPE samples assessed using the DASL WG assay, following selection
of the best performing probes
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marker discovery. Over the past few years, there has
been considerable interest in using FFPE tissue for
translational research, following the success of the
success of the Recurrence score® and the PAM50
score, which have demonstrated that reliable tests can
be performed using FFPE tissue and used in routine
clinical practice [15, 16]. This has led to improve-
ments in the methods used for RNA extraction and
in platforms used for FFPE analysis. Multiple tests
have been developed for breast, lung, prostate, and
colorectal cancer, which can potentially use FFPE
samples for molecular marker analysis [17–19].
This is one of the first studies to assess matched FF
and FFPE tissues with two different gene expression
platforms, and to analyse the concordance of data gener-
ated. If progress is to be made with the analysis of FFPE
tissue, it is imperative that the limitations of the
platforms are investigated. Our study showed that
comparable profiles and biological information could
be derived.
In a similar study to this, April et al. reported
that > 88 % of probes were reliably detected using RNA
from both sources, which is comparable to our results [7].
The quality and quantity of RNA that can be extracted
from FFPE tissue varies [20]. There are many reasons for
these variations, including RNase degradation and gen-
omic DNA contamination [21]. Bibikova et al. [6] demon-
strated that only 50 % of probes were detected in FFPE
compared to FF tumour specimens using DASL CP; how-
ever, there were differences between this and the DASL
WG array which could account for these differences
[22–24]. Linton et al. used Affymetrix Plus 2.0 arrays and
found that only 50 % of the probes detected in FF samples
were also identified using RNA from FFPE specimens
[25]. This is not surprising as the probes in this array are
not specifically designed for FFPE analysis and the assay
only uses oligo-dT for reverse transcription [26].
Our study carried out a rigorous bioinformatics assess-
ment of the WG DASL platform to validate its role in
assessing FFPE samples. The confounding factors such
as the GC content and the probe annealing position on
the gene are some of the important factors that should
be considered in the data analysis to select appropriate
probes for comparison. Retrospectively, we also noted
that some failed arrays had lower dye incorporation rates
and lower total DNA concentration following the PCR
reaction. This can potentially be used as a quality con-
trol step in the future to improve the data quality. It was
also noted that genes that were shorter were more likely
to be reliably detected than longer ones. This is going to
have implication for selecting the optimal probes for fu-
ture array design.
Ravo et al. analysed the gene expression of matched FF
and FFPE samples on a DASL CP platform and also of FF
samples on an Illumina BeadArray [27]. Their data suggest
that DASL CP is more sensitive than the BeadArray,
Fig. 3 Hierachial clustering of samples assessed using DASL WG assays. FFPE & FF samples assessed using the DASL WG assay clustered together
in the majority of samples (note 99028 F is an outlier as it had very few probes detected)
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Fig. 4 Hierarchical clustering of FF and FFPE samples assessed using the DASL WG assay, and of FF samples assessed using the Illumina BeadArray.
This shows significant clustering of FF and FFPE samples, regardless of whether the DASL WG or the BeadArray (indicated by number only) are used
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especially in the identification of low abundance tran-
scripts, due to the gene-specific RT-PCR process [27].
These two assays have different dynamic ranges, which
also likely contributes to the differences observed. Similar
to this study, where matched RNA was profiled using
DASL WG, Mittempergher et al. also found that profiled
samples clustered according to the RNA source [11].
One of the unique features of our study, compared to
previous reports, is that we used matched FF and FFPE
samples and assessed them using the same platform
(DASL WG). This enabled us to compare the assay and
its performance according to RNA source. Other studies,
such as that of Ravo et al., used FFPE and matched cell
line samples, rather than FF cancer specimens [27]. April
et al. used cancer and matched normal tissue [7], and
Wardell et al. analysed samples using different assays
[9]. Others such as Sadi et al. compared limited number
of probes and Abramovitz et al. compared custom panel of
genes, limiting the value in assessing performance [1, 19].
Development of robust bioinformatics methods for
analysis and interpretation of FFPE data is needed due
to the variable quality of RNA [28]. The close clustering
of two types of samples shows that reliable data can be
generated using FFPE samples, with significant overlap
with profiles from FF samples and thus attesting to the
power of this technology to obtain reliable profiles from
FFPE tissue. Our data confirm those of Mittempergher
et al., which showed that samples profiled using DASL
WG clustered together, irrespective of the source of
RNA. They also observed that hierarchical clustering of
the initial data led to FF and FFPE clustering in groups;
however, following median centering of the log2 trans-
formed data and use of only the 5444 best performing
probes, samples clustered according to type [11]. Our
study confirms these results in and a second platform
was also used to compare results from FF specimens,
adding further evidence of the robustness of the assay.
This confirms the potential of the DASL WG platform
for FFPE analysis. Many groups have reported that
correlations are poorer for genes with low expression
levels. This is of interest as the DASL assay relies on
gene-specific amplification; therefore, the signal would
be expected to be independent of the expression level.
However, it is possible that cDNA synthesis and PCR
are less efficient for genes expressed at low levels, es-
pecially when modification of the 3′ UTR could cause
marked effects.
Conclusions
Together with appropriate histopathological criteria,
molecular classification of cancers can contribute to bet-
ter patient stratification. This is one of the first studies
to assess the DASL WG assay, and importantly to in-
clude a comparison with Illumina BeadArray’s. The data
demonstrate that reproducible, biologically relevant
signatures can be generated using FFPE specimens and
the DASL WG assay. This has marked implications for fu-
ture research using FFPE materials and will impact studies
aimed at molecular marker discovery, especially where
only FFPE is available.
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